Next earnings date: 12 Aug 2025

Nascent Biotech, Inc. – OTC:NBIO

Add to watchlist

$0.001

-0.04

-97.8%

Market closed

Open in about 5 hours

-40.72%

month

-40.72%

quarter

-69.70%

year

Market Cap	14.22M
Enterprise value	N/A

P/E	-3.4
EV/Sales	N/A
EV/EBITDA	N/A
Price/Sales	N/A
Price/Book	-5.95
PEG ratio	-0.06
EPS	N/A

Revenue	N/A
EBITDA	-889.74K
Income	-794.67K
Revenue Q/Q	N/A
Revenue Y/Y	N/A

Profit margin	0%
Oper. margin	0%
Gross margin	0%
EBIT margin	0%
EBITDA margin	N/A

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Nascent Biotech, Inc. (OTC:NBIO): Profit margin
Dec 2021	1M	597.32K	59.73%
Mar 2022	0	-361.36K
Mar 2023	0	-518.05K
Mar 2024	0	-512.57K

Nascent Biotech, Inc. (OTC:NBIO): Debt to assets
Sep 2022	1200995	2.38M	198.91%
Dec 2022	565844	1.92M	341.07%
Mar 2023	255002	1.55M	608.29%
Mar 2024	552120	808.79K	146.49%

Nascent Biotech, Inc. (OTC:NBIO): Cash Flow
Dec 2021	-100.64K	-120.5K
Mar 2022	292.67K	-200K
Mar 2023	-386.57K	0
Mar 2024	-351.73K	100K

Nascent Biotech
Hedge Funds Holdings Q1 2023

0.09% +0.09%

of NBIO is owned by hedge funds

1 +1

hedge funds hold NBIO stock

105K +105K

shares is hold by hedge funds

NBIO hedge funds holdings changes

Nascent Biotech
Insider Trading

Nascent Biotech, Inc. (OTC:NBIO): Insider trades (number of shares)
Period	Buy	Sel
Jul 2022	0	5000
Jan 2023	20000	0
Jun 2023	130000	0

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Purchase	7 Jun 2023	HOLDEN LOWELL THOMAS director, officer..	Common stock	130,000	$0.04	$5,200
Purchase	7 Jun 2023	HOLDEN LOWELL THOMAS director, officer..	Common stock	130,000	$0.04	$5,200
Purchase	27 Jan 2023	HOLDEN LOWELL THOMAS director, officer..	Common Stock	20,000	$0.14	$2,800
Purchase	27 Jan 2023	HOLDEN LOWELL THOMAS director, officer..	Common Stock	20,000	$0.14	$2,800
Sale	21 Jul 2022	HOLDEN LOWELL THOMAS director, officer..	Common Stock	5,000	$0.26	$1,300
Sale	21 Jul 2022	HOLDEN LOWELL THOMAS director, officer..	Common Stock	5,000	$0.26	$1,300
Purchase	26 Dec 2019	HOLDEN LOWELL THOMAS director, officer..	Common Stock	5,000	$0.17	$825
Purchase	26 Dec 2019	HOLDEN LOWELL THOMAS director, officer..	Common Stock	5,000	$0.17	$825
Purchase	3 Oct 2019	HOLDEN LOWELL THOMAS director, officer..	Common Stock	10,000	$0.14	$1,400
Purchase	3 Oct 2019	HOLDEN LOWELL THOMAS director, officer..	Common Stock	10,000	$0.14	$1,400

NBIO insider trading transactions

Nascent Biotech
Executives

Insider	Age	Since	Compensation
Mr. Sean Carrick (1968) Pres, Chief Executive Officer, Sec. & Director	57		$352,000
Mr. Lowell Holden (1943) Chief Financial Officer, Chief Accounting Officer & Director	82		$250,000

Nascent Biotech
Latest News

Tuesday, 30 July 2024
08:00	Nascent Biotech Presents at the July Emerging Growth Conference	accesswire.com
Tuesday, 16 April 2024
08:00	Nascent Prepares for Pivotal Phase II Research with Fresh Manufacturing Run	accesswire.com
Tuesday, 19 March 2024
08:00	Nascent Collaborates With Hypospray Pharma on Proprietary Transdermal Delivery System	accesswire.com
Tuesday, 6 February 2024
07:00	Nascent Biotech and Manhattan BioSolutions Collaborate to Explore Pritumumab Antibody-Drug Conjugates	accesswire.com
Tuesday, 9 January 2024
08:00	Nascent Biotech Receives an Analyst Opinion Suggesting that of the Company is Significantly Under Valued	accesswire.com
Tuesday, 19 December 2023
08:00	Nascent Biotech Completes Payment of Variable Convertible Note in Full to Eliminate Dilution Risk	accesswire.com
Wednesday, 29 November 2023
08:00	Nascent Biotech Granted Japanese Patent for Crossing Blood-Brain Barrier	accesswire.com
Tuesday, 22 August 2023
08:00	Nascent Biotech to Begin Phase II Clinical Trials for Brain Cancer	accesswire.com
Tuesday, 9 May 2023
08:00	Nascent Biotech to Present Phase I Clinical Data at American Society of Clinical Oncology Annual Meeting	Accesswire

Frequently Asked Questions (FAQ)

What's the price of Nascent Biotech stock today?

One share of Nascent Biotech stock can currently be purchased for approximately $0.
When is Nascent Biotech's next earnings date?

Nascent Biotech, Inc. is estimated to report earnings on Tuesday, 12 Aug 2025.
Does Nascent Biotech pay dividends?

No, Nascent Biotech does not pay dividends.
How much money does Nascent Biotech make?

Nascent Biotech has a market capitalization of 14.22M.
What is Nascent Biotech's stock symbol?

Nascent Biotech, Inc. is traded on the OTC under the ticker symbol "NBIO".
What is Nascent Biotech's primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of Nascent Biotech?

Shares of Nascent Biotech can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are Nascent Biotech's key executives?
Nascent Biotech's management team includes the following people:
- Mr. Sean Carrick Pres, Chief Executive Officer, Sec. & Director(age: 57, pay: $352,000)
- Mr. Lowell Holden Chief Financial Officer, Chief Accounting Officer & Director(age: 82, pay: $250,000)
When Nascent Biotech went public?

Nascent Biotech, Inc. is publicly traded company for more then 15 years since IPO on 3 Dec 2009.
What is Nascent Biotech's official website?

The official website for Nascent Biotech is nascentbiotech.com.
Where are Nascent Biotech's headquarters?

Nascent Biotech is headquartered at 6330 Nancy Ridge Drive, San Diego, CA.
How can i contact Nascent Biotech?

Nascent Biotech's mailing address is 6330 Nancy Ridge Drive, San Diego, CA and company can be reached via phone at +61 29615656.

Nascent Biotech, Inc.

nascentbiotech.com

Exchange:

OTC

Full time employees:

Industry:

Biotechnology

Sector:

Healthcare

Nascent Biotech, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of various forms of cancer. It is developing Pritumumab, a drug to treat patients with brain cancer malignancies, such as glioblastoma and malignant astrocytoma, as well as epithelial cancers, including lung, breast, colon, brain, and pancreas cancer. In addition, the company is developing MultiPharm, a proprietary technology platform for cancer therapy, as well as diabetes, autoimmunity, and transplantation. Nascent Biotech, Inc. is based in Vero Beach, Florida.

+61 29615656

6330 Nancy Ridge Drive
San Diego, CA 32960

CIK: 0001622057
ISIN: US63108Q1013
CUSIP: 63108Q101